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METHOD FOR REDUCING THE 
INFLAMMATION AND INDUCING AN 
ANALGESIC EFFECT AND COMPOUNDS 
THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
5 
This application is a divisional patent application of, and 
claims priority to, U.S. patent application Ser. No. 09/010, 10 
162 filed in the United States Patent and Trademark Office 
on Jan. 21, 1998, now U.S. Pat. No. 6,495,514, the entire 
disclosure of which is fully incorporated herein by this 
reference. 







R1 is C1-C10 branched or straight chain alkyl, aryl, an 
amino acid, or a peptide; and 
R2 is hydrogen or lower C1-Cs branched or straight alkyl, 
or the salt or ester thereof, wherein 
the stereochemistry about the carbon-carbon double bond 
is trans. 1. Field of the Invention 
The invention relates to a method for reducing inflam-
mation and a method for inducing an analgesic effect in a 
subject and compounds thereof. 
The invention further relates to a method for inducing an 
20 analgesic effect in a subject, comprising administering to the 
subject an effective amount of the compound having the 
structure I or II: 
2. Background Art 
Inflammatory disease represents a pressing public health 
25 
problem in our society. While rheumatoid arthritis is prob-
ably the most widely known chronic inflammatory disease, 
other examples are ulcerative colitis, Crohn' s disease, gout, 
bursitis and tendinitis. Traditionally, inflammation has been 30 
treated with aspirin-like drugs, steroid based compounds, or 
non-steroidal anti-inflammatory drugs. These drugs are of 
variable effectiveness; however, they are not therapeutic in 
nature. 
Neuropeptides are released from peripheral terminals of 35 
primary afferent sensory nerves and contribute significantly 
to the inflammatory response of a variety of diseases includ-
ing rheumatoid arthritis. Examples of neuropeptides that 
have been investigated extensively are substance P (SP) and 40 
Calcitonin Gene-Related Peptide (CGRP). These neuropep-
tides have been shown to be capable of producing 
vasodilation, increasing vascular permeability, attracting 
and activating phagocytic white blood cells, releasing 
cytokines, lysosomal enzymes and prostaglandins from 45 
these cells, increasing the expression of adhesion molecules 





R1 is C1-C10 branched or straight chain alkyl, aryl, an 
amino acid, or a peptide; and 
R2 is hydrogen or lower C1-Cs branched or straight alkyl, 
or the salt or ester thereof, wherein 
the stereochemistry about the carbon-carbon double bond 
is trans. 
The invention further provides a compound for reducing 
inflammation and/or inducing an analgesic effect having the 
structure II: 
(II) 
Several pharmacological approaches to reduce the neu-
rogenic component of inflammation have been evaluated; 
however, a means for reducing inflammation by reducing the 
release of a neuropeptide responsible for inflammation has 
not been developed. 
50 wherein, R1 is an N-acyl amino acid or peptide, 
or the salt or ester thereof. 
Thus, there remains a need in the art for reducing inflam-
mation in a subject. Applicants have discovered such a 
method, and have also discovered a method for inducing an 
analgesic effect in a subject. The prior art does not disclose 
the methods or compounds such as those described and 
claimed herein. 
SUMMARY OF THE INVENTION 
Additional advantages of the invention will be set forth in 
part in the description which follows, and in part will be 
obvious from the description, or may be learned by practice 
55 of the invention. The advantages of the invention will be 
realized and attained by means of the elements and combi-
nations particularly pointed out in the appended claims. It is 
to be understood that both the foregoing general description 
and the following detailed description are exemplary and 
60 explanatory only and are not restrictive of the invention, as 
claimed. 
In accordance with the purpose(s) of this invention, as 
embodied and broadly described herein, this invention, in 
one aspect, relates to a method for reducing inflammation in 65 
a subject, comprising administering to the subject an effec-
tive amount of the compound having the structure I or II: 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a graph showing the effect of PBAin vivo on the 
activity of serum PAM and PGL. 
FIG. 2 is a graph showing the dose-response effect of PEA 
on serum PAM activity in normal rats. 
US 6,962,899 B2 
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FIG. 3 is a graph showing the effect of PEA on 
carrageenan-induced edema in rats. 
FIG. 4 is a graph showing the effect of PEA on carrag-
eenan edema when administered two hours after the admin-
istration of the phlogistic agent. 
FIG. 5 is a graph showing the effect of continuous 
administration of PEA on carrageenan edema, serum PAM 
activity and SP levels in rat hind paws. 
FIG. 6 is a graph showing the effect of PEA on phenyl-
p-quinone-induced writhing in mice. 
FIG. 7 is a graph showing the effect of PEA on 
acetylcholine-induced writhing in mice. 
DETAILED DESCRIPTION OF IBE 
INVENTION 
Before the present compositions of matter and methods 
are disclosed and described, it is to be understood that this 
invention is not limited to specific synthetic methods or to 
particular formulations, as such may, of course, vary. It is 
also to be understood that the terminology used herein is for 
the purpose of describing particular embodiments only and 
is not intended to be limiting. 
In this specification and in the claims which follow, 
reference will be made to a number of terms which shall be 
defined to have the following meanings: 
The singular forms "a," "an" and "the" include plural 
referents unless the context clearly dictates otherwise. 
In accordance with the purpose(s) of this invention, as 
embodied and broadly described herein, this invention, in 
one aspect, relates to a method for reducing inflammation in 
a subject, comprising administering to the subject an effec-





matory process. Inflammatory neuropeptides can possess a 
terminal amide group. Examples of these inflammatory 
neuropeptides include, but are not limited to, substance P 
(SP) and Calcitonin Gene-Related Peptide (CGRP). 
The present invention discloses a method for reducing 
inflammation in a subject. The term "reducing" refers to a 
decrease in inflammation or the prevention of further inflam-
mation by an inflammatory neuropeptide. One approach to 
reduce the inflammation process is to prevent the formation 
10 
of an active amidated inflammatory neuropeptide from an 
inactive precursor by inhibiting the amidating enzymes that 
convert the inactive precursor to the active inflammatory 
amidation of the neuropeptide that results in an inflamma-
tory neuropeptide. In one embodiment, inflammation is 
reduced by inhibiting the amidation of an inactive precursor, 
15 preferably a neuropeptide. In another embodiment, inflam-
mation is reduced by inhibiting or preventing a-amidation of 
a neuropeptide to produce an inflammatory neuropeptide. 
The term "a-amidation" is defined as a process that converts 
a terminal functional group on a neuropeptide to a terminal 
20 amino group. In one embodiment, the terminal functional 
group can be an a-hydroxycarboxylic acid. Once the neu-
ropeptide undergoes a-amidation, the inflammatory neu-
ropeptide is produced. Examples of inflammatory neuropep-
tides include, but are not limited, to Substance P (SP) and 
25 Calcitonin Gene-Related Peptide (CGRP). 
In another embodiment of the invention, a method for 
reducing inflammation in a subject is accomplished by 
inhibiting the activity of an amidating enzyme. By inhibiting 
the activity of an amidating enzyme, the amount of inflam-
30 matory neuropeptide that is produced is subsequently 
reduced. Compounds I and II can inhibit the activity of an 
amidating enzyme. In one embodiment, the amidating 
enzyme that is inhibited is peptidylglycine 
35 
a-monooxygenase (PAM). 
It has been discovered that compounds having the struc-
ture I and II can inhibit the activity of an amidating enzyme. 
(II) 40 
In the case of structure I, when R2 is lower Ci-Cs branched 
or straight alkyl, the alkyl group is stereotopically oriented 
(R or S configuration) so that it does not interfere with the 
compound binding to the amidating enzyme. In one 
embodiment, when the structure is I, R1 is phenyl and R2 is 0 
R1~C02H wherein, 
R1 is Ci-C10 branched or straight chain alkyl, aryl, an 
amino acid, or a peptide; and 
R2 is hydrogen or lower C1-Cs branched or straight alkyl, 
or the salt or ester thereof, wherein 
hydrogen. This compound is named trans-4-phenyl-3-
butenoic acid, herein referred to as PEA. 
In another embodiment, when the compound has the 
45 structure II, R 1 is an amino acid or peptide. Peptide can also 
refer to a polypeptide. In another embodiment, when the 
structure is II, R1 is an N-acyl-amino acid. In yet another 
embodiment, when the compound has the structure II, the 
the stereochemistry about the carbon-carbon double bond 50 
compound is N-acetyl-phenylalanyl acrylic acid. In yet 
another embodiment, when the compound has the structure 
II, R 1 is phenyl. is trans. 
Neuropeptides contribute significantly to the inflamma-
tory response. Approximately 50% of the known neuropep-
tides are synthesized as biologically inactive glycine-
extended precursors that require a carboxy-terminal post-
translational amidation for biological activity. Amidation 
enzymes are responsible for the conversion of the carboxyl 
group of the neuropeptide to the corresponding amide group. 
The term "amidation enzyme" is defined as the enzymes 
which can convert the carboxyl group of a neuropeptide to 
an amide group. The two amidating enzymes peptidylgly-
cine a-monooxygenase (EC 1.14.17.3), herein referred to as 
PAM, and peptidylamidoglycolate lyase (EC 4.3.2.5), herein 
referred to as PGL, working sequentially can also produce 
an inflammatory neuropeptide from an inactive precursor 
peptide. The term "inflammatory neuropeptide" is defined as 
an neuropeptide that plays a biological role in the inflam-
Compounds having the structure I and II can inhibit the 
activity of an amidating enzyme from 10 to 100%. In one 
embodiment, the lower limit for inhibiting the activity of the 
55 amidating enzyme is 10, 20, 30, 40 or 50% and the upper 
limit is 50, 60, 70, 80, 90 or 100%. The method of the 
present invention is designed to inhibit the activity of the 
enzyme which carries out the first step in the amidation 
reaction at least one amidating enzyme. Depending on the 
60 selection and amount of compounds having the structure I or 
II administered to a subject, it may be possible to inhibit the 
activity of two or more amidating enzymes responsible for 
inflammation. The inhibition of the amidating enzyme may 
also occur reversibly or irreversibly. Once again, the selec-
65 tion of the compound having the structure I or II will 
determine if the inhibition of the amidating enzyme is 
reversible or irreversible. 
US 6,962,899 B2 
5 
The compounds of the present invention may also inter-
fere with mediators of inflammation. Examples of inflam-
matory mediators include but are not limited to serotonin 
and bradykinin. 
As described above, the method of the present invention 
reduces inflammation by reducing the amount of an inflam-
matory neuropeptide. In one embodiment, the method of the 
present invention reduces the amount of a neuropeptide in a 
tissue. The tissue can be any tissue that is susceptible to an 
inflammatory process. In a preferred embodiment, the 
amount of inflammatory neuropeptide is reduced in a joint, 
internal organs or other sites susceptible to inflammation. 
Upon administration of compounds having the structure I 
or II, inflammation is immediately reduced in an inflamed 
tissue. Compounds having the structure I and II can reduce 
inflammation over a short or long period of time depending 
on the selection of compounds having the structure I or II, 
the amount administered and the frequence and interval of 
administration. In one embodiment, inflammation is reduced 
6 
The methods and compounds of the present invention can 
reduce inflammation and/or induce an analgesic response in 
a subject. In one embodiment, the subject is a mammal, 
reptile, bird or fish. In another embodiment, the subject can 
5 be a human or another animal, wherein the animal can 
particularly be a domestic, food producing or wild animal. 
Examples of domestic animals include but are not limited to 
dogs, cats, horses or birds. Examples of food producing 
animals include but are not limited to cows, pigs, chickens 
10 or sheep. Examples of wild animals include but are not 
limited to lions, tigers, elephants, monkeys or bears. 
As used herein to describe the present anti-inflammatory 
and analgesic methods, "an effective amount" of a com-
pound is that amount capable of achieving the desired effect. 
15 As described above, an effective amount can be an amount 
sufficient to reduce inflammation and/or induce an analgesic 
effect. Such amounts can readily be determined for any 
specific composition using standard methods and as 
described herein. 
in the tissue for 0.5 to 12 hours. In another embodiment, the 20 
lower limit for inhibition of inflammation is 0.5, 1, 2, 3, 4, 
The exact amount of the compound having the structure 
I or II required to reduce inflammation and/or induce an 
analgesic effect will vary from subject to subject, depending 
on the species, age, weight and general condition of the 
subject, the severity of the disease, infection or condition 
that is being treated or prevented, the particular compound 
used, its mode of administration, and the like. Thus, it is not 
5 or 6 hours and the upper limit of inhibition is 6, 7, 8, 9, 10, 
11 or 12 hours. As described above, inflammation is inhib-
ited by reducing the amount of an inflammatory neuropep-
tide present in a tissue. In one embodiment, the amount of 25 
inflammatory neuropeptide in an inflamed tissue of a subject 
is reduced from 10 to 100%. In another embodiment, the 
lower limit for reduction of an inflammatory neuropeptide in 
a tissue is 10, 20, 30, 40, 50% and the upper limit is 50, 60, 
70, 80, 90, 95 or 100%. Moreover, compounds having the 30 
structure I and II can be administered concurrently or 
sequentially to reduce inflammation in a subject. 
possible to specify an exact amount. However, an appropri-
ate amount may be determined by one of ordinary skill in the 
art using only routine experimentation given the teachings 
herein. In one embodiment, the amount of compound I or II 
that is administered is from 10 to 1000 mg/kg bodyweight of 
the subject. In another embodiment, the lower limit is 10, 20, 
30, 40, 50, 60, 70, 80, 90, 100, 200 or 300 mg/kg body-
weight of the subject and the upper limit is 300, 400, 500, 
600, 700, 800, 900 or 1000 mg/kg bodyweight of the subject. 
A single administration may be sufficient, depending upon 
The invention further relates to a method for inducing an 
analgesic effect in a subject, comprising administering to the 
subject an effective amount of a compound having the 35 





R1 is CcC10 branched or straight chain alkyl, aryl, an 
amino acid, or a peptide; and 
R2 is hydrogen or lower C1-C5 branched or straight alkyl, 
or the salt or ester thereof, wherein 
the stereochemistry about the carbon-carbon double bond 
is trans. 
In one embodiment, compounds having the structure I and 
II can induce an analgesic effect in a subject. In yet another 
embodiment, compounds having the structure I and II can 
induce an analgesic effect and reduce inflammation in a 
subject. Moreover, compounds having the structure I and II 
can be administered concurrently or sequentially to reduce 
inflammation and induce an analgesic effect in a subject. 
The site of action of the analgesic effect can be central or 
peripheral. Mediators involved in the production of periph-
eral pain include, but are not limited to, neuropeptides, 
bradykinin, and prostaglandins. Examples of neuropeptides, 
in particular, inflammatory neuropeptides, include, but are 
not limited to, Substance P and Calcitonin Gene-Related 
Peptide. Examples of prostaglandins are known in the art. 
the condition being treated or prevented; however, it is also 
contemplated that multiple administrations may be admin-
istered. Administrations after the initial administration may 
40 be of lower dosage than the initial dosage. 
The anti-inflammatory and/or analgesic compounds hav-
ing the structure I and II can be administered to a subject 
using a variety of methods known in the art. In one 
embodiment, the compounds can be delivered parenterally, 
45 by injection, such as intramuscular, intraperitoneal, intrave-
nous or subcutaneous injection, or by inhalation. In another 
embodiment, when the mode of administration is by oral 
delivery, and R1 is an amino acid or peptide, then R1 should 
preferably be a D-amino acid(s) or a peptidomimetic. A 
50 peptidomimetic useful in the present invention is a com-
pound derived from a peptide or protein. Peptidomimetics 
bridge the gap between simple peptides and the nonpeptide 
synthetic structures and, as such, may be useful in delineat-
ing pharmacophores and facilitate the translation of a pep-
55 tide into small nonpeptide compounds. A peptidomimetic 
can also be an organic molecule that mimicks a property of 
a peptide ligand. 
Depending on the intended mode of administration, com-
pounds having the structure I or II can be in pharmaceutical 
60 compositions in the form of solid, semi-solid or liquid 
dosage forms, such as, for example, tablets, suppositories, 
pills, capsules, powders, liquids, suspensions, lotions, 
creams, gels, or the like, preferably in unit dosage form 
suitable for single administration of a precise dosage. The 
65 compositions will include, as noted above, an effective 
amount of compounds having the structure I or II, possibly 
in combination with a pharmaceutically acceptable carrier 
US 6,962,899 B2 
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and, in addition, may include other medicinal agents, phar-
maceutical agents, carriers, adjuvants, diluents, etc. 
8 
EXAMPLES 
Synthesis of N-Ac-L-Phe-Acrylic Acid 
For oral administration, fine powders or granules may 
contain diluting, dispersing, and/or surface active agents, 
and may be presented in water or in a syrup, in capsules or 
5 
sachets in the dry state, or in a nonaqueous solution or 
suspension wherein suspending agents may be included, in 
tablets wherein binders and lubricants may be included, or 
To a solution ofN-Ac-L-Phe (5.0 g, 24.1 mmol) in 120 ml 
of ethanol was added a few drops of concentrated HCl. The 
reaction mixture was refluxed overnight, then concentrated 
under reduced pressure. The residual solid was dissolved in 
ethyl acetate, washed twice with dilute NaHC03 , then once 
with water. The organic phase was dried over MgS04 , 
concentrated under reduced pressure, and dried under 
vacuum, to give N-Ac-Phe-OEt as a white solid. 
in a suspension in water or a syrup. Where desirable or 
necessary, flavoring, preserving, suspending, thickening, or 
emulsifying agents may be included. Tablets and granules 10 
are preferred oral administration forms, and these may be 
coated. 
n-BuLi (17.0 ml, 42.5 mmol) is slowly added to a solution 
of dimethyl methylphosphonate ( 4.6 ml, 42.4 mmol) in 50 
ml anhydrous THF kept at - 78° C., under N2 . The reaction 
mixture is stirred, at - 78° C. for 15 minutes, at which time 
a precipitate formed. N-Ac-Phe-OEt (5.0 g, 21.2 mmol) is 
then added all at once. The reaction mixture was slowly 
Parenteral administration, if used, is generally character-
ized by injection. Injectables can be prepared in conven-
tional forms, either as liquid solutions or suspensions, solid 
forms suitable for solution or suspension in liquid prior to 15 
injection, or as emulsions. 
brought to room temperature, and stirred overnight (the 
reaction was monitored by TLC (eluting solvent: EtOAc)). 
The reaction was then quenched by the addition of water. 
The invention further relates to a compound for reducing 
inflammation and/or inducing an analgesic effect having the 
structure II: 
wherein, R1 is an N-acyl amino acid or peptide, 
or the salt or ester thereof. 
(II) 
In one embodiment, the compound having the structure II 
is N-acetyl-phenylalanyl acrylic acid. 
A general procedure for preparing compounds having the 


















Treatment of the ester 1, wherein R1 is C1-C10 branched 
straight chain alkyl, aryl, a residue of an amino acid or 
peptide and R3 is CcC5 branched or straight chain alkyl or 
aryl, with the phosphodiester compound 2 results in the 
formation of compound 3. The addition of 4 to 3 in the 
presence of a base followed by hydrolysis with water 
produces the a,~-unsaturated ester 5. Enzymatic hydrolysis 
of 5 produces the acid compound 6, which can readily be 
converted to the salt using techniques known in the art. 
The present invention may be understood more readily by 
reference to the following detailed description of preferred 
embodiments of the invention and the Examples included 
therein. 
20 Ether is then added, the two layers separated, and the 
aqueous layer extracted with ether. The ether extracts were 
discarded. The aqueous layer is then acidified by the addi-
tion of 4 N HCl and extracted with methylene chloride. The 
combined methylene chloride extracts are dried over 
25 MgS04 , filtered, and concentrated under reduced pressure. 
The product, N-Ac-L-Phe-a-ketophosphonate, is purified by 
flash chromatography (eluting solvent: CHCl3 /MeOH 10:1), 
to give pure bright yellow oil (5.0 g, 16.1 mmol, 76%). 
A mixture of methyldimethoxyacetate (10.0 g, 74.5 
30 mmol), glyoxilic acid monohydrate (6.8 g, 73.9 mmol), and 
p-toulenesulfonic acid (cat.) is stirred at 80° C. overnight. 
The reaction mixture is then cooled to 0° C. and P2 0 5 (7.8 
g) is slowly added. The thick slurry is then stirred at 80° C. 
for 4 hours and distilled under vacuum to give methylgly-
35 oxylate as a yellow oil which quickly thickens and turns 
clear. 
Potassium carbonate ( 4.45 g, 32.2 mmol) dissolved in 20 
ml water is added to a mixture of N-Ac-Phe-a-
ketophosphonate (5.04 g, 16.1 mmol) and methylglyoxylate 
40 (1.4 g, 15.9 mmol) in 10 ml water at 5° C. A precipitate 
forms immediately. The reaction mixture was stirred at 5° C. 
for 15 minutes. The solid methyl N-Ac-L-Phe acrylate is 
then collected by suction, washed with cold water, dried 
under vacuum over P2 0 5 , and recrystallized from hot ethyl 
45 acetate/hexane, yielding 1.3 g ( 4. 72 mmol, 29%) of pale 
yellow solid. 
To a solution of methyl N-Ac-L-Phe acrylate (0.5 g, 1.81 
mmol) in 7 ml of methanol is added 75 ml of 0.1 M 
phosphate buffer, pH 7.0, at which time the solution turns 
50 cloudy. Pig Liver Esterase (5000 U) is then added and the 
reaction mixture stirred vigorously at 30° C. for 48 hours 
(the reaction mixture is then clear; the progress of the 
reaction is monitored by TLC, eluting solvent: EtOAc). The 
reaction mixture is then washed twice with ether (an emul-
55 sion forms, ether extracts discarded), acidified by the addi-
tion of 4 N HCl (turns cloudy), and saturated with NaCL The 
aqueous layer is then thoroughly extracted with methylene 
chloride (an emulsion forms). The combined organic 
extracts are dried over MgS04 , concentrated under reduced 
60 pressure, and dried under vacuum to give N-Ac-L-Phe-
acrylic acid as a white solid (0.255 g, 0.98 mmol, 54%). 
Elemental Analysis: Calculated for C14H15N04 +Y4 H2 0; 
C, 63.27%; H, 5.88%; N, 5.27%; Found: C, 63.26%; H, 
5.85%; N, 5.22%. 1H NMR (DSMO-d6 DMSO -2.49 ppm): 
65 ll 1.78 (s, 3H); 2.72-3.07 (m, 2H); 4.70, (m, lH); 6.56 (d, 
lH, 1=15.9 Hz); 7.09 (d, lH, 1=15.9 Hz); 7.22 (m, SH); 8.42 
(d, lH). M.P.: decomposes. MS (FAE+): 262.3 (M+l); 




volumes (edema) were measured plethysmographically by 
displacement of mercury at 0, 1, 2, 3, 4 and 6 hours post 
administration of carrageenan, 30 minutes after bradykinin 
and 1 hour after serotonin. Swelling was determined by 
Adult male, Sprague Dawley rats (175-225 g) and male 
ND4 Swiss Webster mice (lS-20 g) were purchased from 
Harlan Sprague Dawley, Inc. (Indianapolis, Ind.), housed in 
appropriate caging facilities and allowed food and water ad 
libitum. All experiments using animals were approved by 
the Institutional Animal Care and Use Committee of Mercer 
University (Macon, Ga.). 
Drugs and Reagents 
5 subtracting the volume (ml) of the right hind paw from that 
of the left. PEA was administered subcutaneously 30 min-
utes before the administration of carrageenan and serotonin 
and one hour before bradykinin. In those experiments in 
which PEA was delivered continuously to rats over a 7 day 
10 period prior to the administration of carrageenan, ALZET 
osmotic pumps (Palo Alto, Calif.) were filled with drug and 
implanted subcutaneously between the scapulae into anes-
thetized rats. 
PEA used in all experiments was purchased from Aldrich 
Chemical Co. (Milwaukee, Wis.) and recrystallized from hot 
ethyl acetate. For all injections, PEA was dissolved in saline, 
the pH adjusted with sodium hydroxide to 7.5 and admin-
istered subcutaneously (between the scapulae) using a con-
stant volume (2 ml/kg). Type IV, lambda carrageenan, 15 
bradykinin acetate, serotonin hydrochloride, phenyl-p-
quinone and acetylcholine chloride were all purchased from 
Sigma Chemical Co (St. Louis, Mo.). Bovine liver catalase 
(65,000 units/mg) was purchased from Boehringer Man-
nheim (Indianapolis, Ind.). a-Hydroxyhippuric acid was 20 
purchased from Aldrich and recrystallized before use. TNP-
D-Tyr-Val-Gly was synthesized as disclosed in Katopodis 
and May (Biochemistry 29, 4541-454S, 1990). All other 
reagents, solvents and chemicals were of analytical grade. 
Evaluation of PAM and PGL Activity 
Extraction and Quantitation of SP Levels 
The effects of PEA on levels of SP were evaluated using 
a modification of a method previously disclosed in Ahmed 
et al. (Peptides 15, 317-322, 1994). Briefly, at different 
times following the administration of carrageenan, hind paw 
ankle joints were removed, immediately frozen on dry ice 
and stored at -S0° C. until assayed for SP. After the frozen 
sample was weighed, it was boiled for 7 minutes as a 10% 
w/v solution of2M acetic acid in 4% EDTA, pH 3.5, cut into 
small pieces and boiled for an additional 7 minutes. Samples 
were then homogenized for 60 seconds in a Brinkmann 
25 Polytron (Westbury, N.Y.), sonicated for 30 seconds and 
centrifuged at 3000xg for 20 minutes. Supernatants were 
lyophilized and then diluted in radioimmunoassay (RIA) 
buffer prior to analysis. SP levels were determined from 
Male rats were fasted overnight and anesthetized with 
ether to obtain blood samples for measuring PAM and PGL 
activity in serum. Blood (0.5 ml) was collected from the tail 
vein at different times and spun at 14,000xg for 5 minutes. 
Serum was collected and stored at - 70° C. until assayed. 30 
PAM activity was determined based on the procedure dis-
closed in Katopodis et al. (Biochemistry 30, 61S9-6194, 
1991). Briefly, 50 µl of serum sample (enzyme source) was 
added to 200 µl of the assay mixture which contained 
tripeptide TNP-D-Tyr-Val-Gly as the enzyme substrate (40 35 
µM), copper sulfate (15 µM), L-ascorbate (4 mM) and 
catalase (1 mg/ml) in MES buffer (100 mM, pH 6.5). After 
a 30 minute incubation period at 37° C., an aliquot (90 µl) 
was quenched with 10 µl of HC104 (3M) and centrifuged at 
14,000xg for 5 minutes. A 20 µl aliquot was removed and 40 
used to assay for product using reverse phase HPLC at 344 
nm on a CS column with a mobile phase of 56% water/0.1 % 
trifluoroacetic acid/44% acetonitrile at a flow rate of 1.5 
mL/min. In this manner, both TNP-D-Tyr-Val-NH2 as well 
as the TNP-D-Tyr-Val-a-hydroxyGly were quantitated 45 
simultaneously. PGL activity was assayed by measuring the 
conversion of a-hydroxyhippuric acid to benzamide as 
disclosed in Katopodis and May (Biochemistry 29, 
4541-454S, 1990). Briefly, 50 µl of the serum sample was 
added to 200 µl of a 100 mM MES buffer solution (pH 6.5) 50 
containing 2 mM of the enzyme substrate. After incubation 
for 30 minutes at 37° C., an aliquot of the assay mixture was 
quenched with 3M HC104 , centrifuged at 14,000xg and 20 
µl used to analyze for benzamide product by HPLC using a 
these samples by using a commercially available RIA kit 
(INCSTAR, Stillwater, Minn.). Initial experiments con-
ducted to insure the specificity of the substance P antibody 
for SP found the cross-reactivity for the glycine-extended 
precursor to be 1.7% at concentrations up to 100 nanograms/ 
ml. 
Analgesic Assays 
The effects of PEA on the perception of pain was evalu-
ated using several different animal models. The spinally-
mediated tail-flick response to heat in fasted rats (250--290 
g) was used by measuring the withdrawal latency following 
immersion of the rodent's tail (2") into hot water (50° C.). 
PEA at several different dose levels was administered sub-
cutaneously and the time to tail withdrawal was measured at 
0, 15, 30 and 60 minutes post-drug administration. The 
analgesic effects of PEA were also evaluated in fasted mice 
following the injection of either phenyl-p-quinone or ace-
tylcholine. Male, ND4 Swiss mice (15-20 g) were dosed 
subcutaneously with PEA or saline followed immediately by 
the injection of phenyl-p-quinone (2 mg/kg i.p.). After 5 
minutes, the number of writhes (abdominal constrictions 
along with contortion of the trunk and extension of the 
hindlimbs) was counted over the next 10 minutes. When 
acetylcholine (6 mg/kg i.p.) was used as the noxious agent, 
PEA was administered subcutaneously 15 minutes before 
the administration of the algesic agent. The number of 
writhes produced was counted over the last 5 minutes 
following the algesic agent. 
Statistical Analysis 
Data are presented as mean responses±S.E.M. Two way 
analysis of variance for repeated measures was used to test 
CS reverse phase column. Product detection was performed 55 
at 225 nm using a mobile phase of SO% water/0.1 % trifluo-
roacetic acid/20% acetonitrile at a flow rate of 1.5 mL/min. 
Enzyme activity was expressed as milliunits per milliliter 
which is the amount of enzyme required to produce one 
nanomole of product. 60 for significance. Comparison of means was performed by 
using Tukey's post hoc tests. A probability of P<0.05 was 
considered statistically significant. 
Carrageenan Edema, Bradykinin and Serotonin Edemas 
Carrageenan, bradykinin and serotonin edemas were 
induced in anesthetized, male Sprague-Dawley rats 
(150-175 g) by injecting 0.5 mg (0.05 ml) of carrageenan, 
50 µg (0.1 ml) of bradykinin and 20 µg (0.1 ml) of serotonin, 65 
respectively, into the subplantar region of the left hind paws; 
the contralateral hind paws received saline only. Hind paw 
Reduction of Inflammation by PEA 
Experiments were conducted to determine if the effects of 
PBAon PAM and PGL activity in vivo were similar to those 
observed in vitro.As shown in FIG. l, PBA(500 mg/kg s.c.) 
significantly inhibited (>90%) the activity of PAM in serum 
US 6,962,899 B2 
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within 1 hour following the administration of a single dose 
to conscious rats. This magnitude of inhibition remained 
during the first 3 hours following administration, decreased 
to 43% inhibition by 6 hours, and was not significantly 
different from control values after 24 hours. This same dose 
of PEA had no effect on serum PGL activity during the 24 
hour observation period demonstrating the ability of PEA to 
selectively inhibit PAM activity. This inhibitory effect of 
PEA on serum PAM activity was also found to be dose-
related (FIG. 2) with the 50 and 150 mg/kg doses having 
similar time-courses of inhibition but of lesser magnitude 
than the effects caused by the 500 mg/kg dose. 
12 
significant inhibition of hind paw swelling for up to 6 hours 
post-phlogistic agent. 
Since these results suggested that the pharmacokinetics of 
PEA were responsible for its short duration of action in 
5 carrageenan edema, experiments were conducted in which 
PEA was administered to rats via osmotic pumps to prolong 
its duration of action. Initial experiments using this method 
of drug delivery were designed to determine if continuous 
release of PBA(50 to 100 mg/kg/hr s.c.) over a 7 day period 
10 would produce a sustained reduction in serum PAM activity. 
Serum samples were taken every other day for analysis of 
PAM activity. Results from this study demonstrated that this 
method of dosing with PEA produced a sustained reduction 
(> 75%) in PAM activity throughout the 7 day dosing period. 
Based on these results, this same dosing protocol was 
used to evaluate the effects of PEA on carrageenan edema in 
animals. Animals were treated with PEA (75 mg/kg/hr) for 
1 week, and then carrageenan was administered into the 
subplantar region of the hind paw. The degree of inflamma-
These results show that PEA is capable of producing an 
anti-inflammatory effect in vivo since inhibition of PAM 
activity would result presumably in lowering of endogenous 
levels of amidated neuropeptides such as SP and CGRP. 15 
Therefore, experiments were conducted to determine if PEA 
had any effect on inflammation induced by the subplantar 
injection of carrageenan. As seen in FIG. 3, the subcutane-
ous administration of PEA 30 minutes before the phlogistic 
agent produced a dose-related inhibition of hind paw edema 20 tion as well as serum PAM activity and SP levels in hind paw 
tissue were measured at different time periods. Results of 
these experiments are shown in FIG. S. As expected, carra-
geenan produced a time-dependent increase in hind paw 
volume in control animals which reached a peak 3 hours 
at 2 and 3 hours post-administration of the phlogistic agent. 
This inhibitory effect was greatest at 2 hours with the 250 
and 500 mg/kg doses producing 43 and 67% inhibition, 
respectively. A similar time-course of inhibition of carrag-
eenan edema was observed in these animals following i.p 
administration of PEA 
Bradykinin and serotonin are two mediators released early 
during acute inflammation, and have been suggested to play 
an important role during the early phase of carrageenan 
edema. Because PEA appeared to be more effective during 
the early phase of carrageenan edema, experiments were 
conducted to determine if PEA was capable of inhibiting 
hind paw swelling produced by these two mediators. It is 
clear from the data shown in Table 1 that PEA lacked 
significant inhibitory activity on edema produced by either 
bradykinin or serotonin at a dose that produced significant 
inhibition of carrageenan edema. 
TABLE 1 
Hind Paw Volume (mL ± S.E.M.) 
Inhibition 
Phlogistic Agent Controls PEA (%) 
Carra gee nan a 0.93 ± 0.12 0.31 ± 0.07 66.7b 
Eradykininc 0.39 ± 0.05 0.29 ± 0.04 25.6 
Serotonin ct 0.81 ± 0.07 0.66 ± 0.03 18.5 
Male, Sprague-Dawley rats were dosed with PEA s.c. 30 minutes before 
carrageenan and serotonin and 1 hour before bradykinin. Hind paw vol-
umes were measured plethysmographically by displacement of mercury. 
'Carrageenan (0.05 mL of 1 % solution) was injected into left hind paw. 
Right hind paw received saline. Paws were measured 2 hours after phlo-
&istic agent. 
Statistical significance (P < .05) compared to controls; n ~ 8 for each 
assay. 
cEradykinin (50 µg) was injected into the left hindpaw. Paws were mea-
sured 30 minutes after the phlogistic agent. 
ctserotonin (20 µg) was injected into the left hindpaw. Paws were mea-
sured 1 hour after phlogistic agent. 
The reduced effectiveness observed with PEA during the 
late phase of carrageenan edema (at 3 hours) could be due 
to the drug having a short duration of action rather than a 
lack of activity. To evaluate this possibility, PEA was 
administered to animals 2 hours after the induction of 
inflammation. As seen in FIG. 4, PEA inhibited the con-
tinuous increase in hind paw swelling observed in control 
animals at 3, 4 and 6 hours post-administration of the 
phlogistic agent. The 100 mg/kg dose was only effective at 
hour 3 while the 250 and 500 mg/kg doses produced 
25 post-administration of the phlogistic agent (FIG. Sa). While 
serum PAM activity did not change significantly in these 
animals (FIG. Sb), there was a significant increase in levels 
of SP in the inflamed hind paws during the first 2 hours after 
carrageenan administration (FIG. Sc). Interestingly, in ani-
30 mals treated for 7 days with PEA, both serum PAM activity 
and SP levels in hind paw tissue were significantly reduced 
compared to controls when measured prior to the adminis-
tration of carrageenan (FIGS. Sb and c, time 0). In those 
animals treated with PEA, there was a significant inhibition 
35 of carrageenan edema at each time period (FIG. Sa). This 
inhibition of hind paw swelling by PEA correlated with its 
ability to inhibit serum PAM activity and reduce SP levels in 
hind paw tissue of animals administered carrageenan (FIGS. 
40 
45 
Sb and c). 
The results of the studies with PEA in carrageenan edema 
clearly demonstrate that PEA is capable of inhibiting an 
acute inflammatory response. These results illustrate that the 
enzyme PAM may be an attractive target for the pharmaco-
logical control of acute inflammation. 
Induction of an Analgesic Effect by PEA 
Since most anti-inflammatory drugs also have analgesic 
activity, experiments were conducted to determine if PEA 
possessed the ability to increase the threshold to pain. Initial 
experiments were performed using the rodent tail-flick assay 
50 to determine if PEA possessed any central analgesic activity 
following acute administration. After obtaining baseline 
values, PEA was administered subcutaneously to rats fol-
lowed by immersion of the rodent tail into 50° C. water and 
measuring the time to tail withdrawal at 15, 30 and 60 
55 minutes post-drug administration. In these experiments, 
PEA did not have any effect on time to tail withdrawal at any 
time period with doses up to 750 mg/kg. 
The phenyl-p-quinone and acetylcholine-induced writh-
ing assays in mice are known to be inhibited by both central 
60 as well as peripheral-acting analgesic agents based on the 
disclosure of Gyires and Torma (Arch. Int. Pharmacodyn. 
267, 131-140, 1984). The i.p. injection of these two sub-
stances produces painful responses (writhes) as manifested 
by a series of abdominal constrictions with contortions of 
65 the trunk and extension of the hindlimbs. Since PEA lacked 
central analgesic activity, these two assays were used to 
evaluate the peripheral analgesic activity of PEA As seen in 
US 6,962,899 B2 
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FIG. 6, PEA produced a significant dose-related inhibition 
of phenyl-p-quinone-induced writhing with greater than 
85% inhibition of writhing occurring at 250 mg/kg. In the 
acetylcholine-induced writhing assay, because the number 
of writhes produced in each control animal was small (1 to 
5 
8), the effects of PEA were expressed as the percentage of 
animals per group that writhed (all or none response) at each 
dose level (FIG. 7). Again, PEA showed significant inhibi-
tory activity with an ED50 of 105 mg/kg which is similar to 
the dose of PEA that reduced phenyl-p-quinone-induced 
writhing by 50%. It is noteworthy that the 100 mg/kg dose 10 
which did not show any activity on carrageenan edema 
produced a significant analgesic effect in both writhing 
assays. 
Throughout this application, various publications are ref-
erenced. The disclosures of these publications in their entire- 15 
ties are hereby incorporated by reference into this applica-
tion in order to more fully describe the state of the art to 
which this invention pertains. 
Although the present process has been described with 
reference to specific details of certain embodiments thereof, 20 
it is not intended that such details should be regarded as 
limitations upon the scope of the invention except as and to 
the extent that they are included in the accompanying 
claims. 
What is claimed is: 
1. A pharmaceutically acceptable compound for admin- 25 
istering to a subject, comprising the structure II: 
(II) 
30 
wherein R 1 is an L-amino acid or salt or ester thereof, or an 
L-amino acid containing peptide or salt or ester thereof; 35 
wherein the carbonyl directly attached to R1 is a carbonyl of 
the L-amino acid salt or ester thereof, or the L-amino acid 
containing peptide or salt of ester thereof; and wherein the 
stereochemistry about the carbon-carbon double bond is 
trans. 40 
2. The compound of claim 1, wherein Rl is an N 
acyl-amino acid. 
3. The compound of claim 1, wherein the compound II is 
N-acetyl-phenylalanyl-acrylic acid. 
4. The compound of claim 1, wherein the compound is 
effective to inhibit amidation of a neuropeptide. 45 
5. The compound of claim 4, wherein the compound is 
effective to inhibit an amidating enzyme. 
6. The compound of claim 5, wherein the amidating 
enzyme is PAM. 
7. The compound of claim 5, wherein the compound is 50 
effective to inhibit the amidating enzyme activity from 10 to 
100%. 
14 
8. The compound of claim 1, wherein the compound is 
effective to reduce inflammation. 
9. The compound of claim 8, wherein the compound is 
effective to reduce inflammation by reducing the amount of 
an inflammatory neuropeptide from 10 to 100%. 
10. The compound of claim 8, wherein the compound is 
effective to reduce the amount of an inflammatory neuropep-
tide in a tissue of the subject. 
11. The compound of claim 10, wherein the tissue is a 
tissue susceptible to an inflammatory process. 
12. The compound of claim 10, wherein the tissue is in an 
inflamed joint. 
13. The compound of claim 1, wherein the compound is 
effective for inducing an analgesic effect. 
14. The compound of claim 1, wherein the compound is 
suitable for administering to the subject orally, 
intravenously, by injection, by intraperitoneal injection and 
by intramuscular injection. 
15. The compound of claim 1, wherein the subject is a 
human or non-human animal. 
16. A pharmaceutical composition comprising: 




wherein R 1 is an L-amino acid or salt or ester thereof, 
or an L-amino acid containing peptide or salt or ester 
thereof; wherein the carbonyl directly attached to R 1 is 
a carbonyl of the L-amino acid salt or ester thereof, or 
the L-amino acid containing peptide or salt of ester 
thereof; and wherein the stereochemistry about the 
carbon-carbon double bond is trans; and 
b) a pharmaceutically acceptable carrier. 
17. The composition of claim 16, wherein Rl is an N 
acyl-amino acid. 
18. The composition of claim 16, wherein the compound 
II is N-acetyl-phenylalanyl-acrylic acid. 
19. The composition of claim 16, wherein the composi-
tion is a solid, semi-solid, or liquid. 
20. The composition of claim 16, wherein the composi-
tion is in the form of a tablet, suppository, pill, capsule, 
powder, suspension, lotion, cream, or gel. 
* * * * * 
